Rahman, R., Trippa, L., Lee, E. Q., Arrillaga-Romany, I., Touat, M., Fell, G., McCluskey, C., Bruno, J., Gaffey, S., Drappatz, J., Lassman, A., Galanis, E., Ahluwalia, M., Colman, H., Nabors, L. B., Hepel, J., Elinzano, H., Schiff, D., Chukwueke, U., Beroukhim, R., Batchelor, T., Nayak, L., McFaline-Figueroa, J. R., Rinne, M., Kaley, T., Lu-Emerson, C., Bi, W. L., Arnaout, O., Haas-Kogan, D., Tanguturi, S., Cagney, D., Aizer, A., Welch, M., Doherty, L., Lavallee, M., Fisher-Longden, B., Dowling, S., Pisano, W., Lapinskas, E., Meredith, D., Chiocca, E. A., Reardon, D., Ligon, K., Alexander, B., & Wen, P. (2021). cTNI-40. EVALUATING FEASIBILITY AND EFFICIENCY OF PHASE II ADAPTIVE PLATFORM TRIAL DESIGNS BASED ON THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGhT) EXPERIENCE. Neuro-oncology, 23, vi68–vi69. http://access.bl.uk/ark:/81055/vdc_100146089895.0x00001b